Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer

British Journal of Cancer

Volumn 114, Issue 2, 2016, Pages 138-145

  Li, Yilin ^a   Gong, Jifang ^a   Zhang, Qiyue ^a   Lu, Zhihao ^a   Gao, Jing ^a   Li, Yanyan ^a   Cao, Yanshuo ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; BIOCHEMICAL EQUIPMENT; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STOMACH CANCER; TREATMENT RESPONSE; ADENOCARCINOMA; ADULT; AGED; BLOOD; COHORT ANALYSIS; FEMALE; GASTROESOPHAGEAL JUNCTION; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; SECONDARY; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR EMBOLISM; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CISPLATIN; COHORT STUDIES; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84955100848     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.417     Document Type: Article

References (37)

1. Alama A, Truini A, Coco S, Genova C, Grossi F (2014) Prognostic and predictive relevance of circulating tumor cells in patients with non-smallcell lung cancer. Drug Discov Today 19(10): 1671-1676.
2. Alix-Panabières C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59(1): 110-118.
3. Balic M, Williams A, Lin H, Datar R, Cote RJ (2013) Circulating tumor cells: from bench to bedside. Annu Rev Med 64: 31-44.
4. Castle J, Shaker H, Morris K, Tugwood JD, Kirwan CC (2014) The significance of circulating tumour cells in breast cancer: A review. Breast 23(5): 552-560.
5. Cohen SJ (2009) Relationship of circulating tumor cells to tumor response, progression-sree durvival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 27(11): 1923-1923.
6. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20(7): 1223-1229.
7. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen L, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8): 781-791.
8. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen L (2005) Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7): 1420-1430.
9. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13(23): 7053-7058.
10. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19): 6302-6309.
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45(2): 228-247.
12. Gao J, Lu M, Yu JW, Li YY, Shen L (2011) Thymidine phosphorylase/betatubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 11: 177.
13. Haber DA, Velculescu VE (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4(6): 650-661.
14. Hartgrink HH, Jansen EPM, van Grieken NCT, van de Velde CJH (2009) Gastric cancer. Lancet 374(9688): 477-490.
15. Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ, Schouwink JH, Wijnands WJ, Kerner GS, Kruyt FA, Tissing H, Tibbe AG, Terstappen LW, Groen HJ (2012) Circulating tumor cells in small-cell lung cancer: A predictive and prognostic factor. Ann Oncol 23(11): 2937-2942.
16. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH (2009) Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 175(2): 808-816.
17. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30(5): 525-532.
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
19. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29(12): 1556-1563.
20. Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang DD, Lin PP, Shen L (2014) Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget 5(16): 6594-6602.
21. Liang H, Kim YH (2013) Identifying molecular drivers of gastric cancer through next-generation sequencing. Cancer Lett 340(2): 241-246.
22. Lim SHS, Becker TM, Chua W, Ng WL, de Souza P, Spring KJ (2014) Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol 67(10): 848-853.
23. Lu M, Gao J, Wang XC, Shen L (2011) Expressions of thymidylate synthase, thymidine phosphorylase, class III beta-tubulin, and excision repair crosscomplementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. Chin J Cancer Res 23(4): 288-294.
24. Matsusaka S, Chin K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, Hatake K (2010) Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci 101(4): 1067-1071.
25. Miyamoto DT, Sequist LV, Lee RJ (2014) Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol 11(7): 401-412.
26. Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35(5): 463-474.
27. Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Buchler MW, Koch M, Weitz J (2010) Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138(5): 1714-1720.
28. Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, Faloppi L, Cascinu S (2009) Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 35(5): 451-462.
29. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G (2009) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 10(3): 233-239.
30. Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT (2013) Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol 14(12): e535-e547.
31. Tang L, Zhao S, Liu W, Parchim NF, Huang J, Tang Y, Gan P, Zhong M (2013) Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer 13: 314.
32. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V (2010) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288(1): 99-106.
33. Tsujiura M, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Otsuji E (2014) Liquid biopsy of gastric cancer patients: circulating tumor cells and cellfree nucleic acids. World J Gastroenterol 20(12): 3265-3286.
34. Wang J, Wang K, Xu J, Huang J, Zhang T (2013) Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: A metaanalysis. PLoS One 8(11): e78070.
35. Wang M, Li Y, Gao J, Li Y, Zhou J, Gu L, Shen L, Deng D (2014) p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer. Med Oncol 31(6): 988.
36. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3(1): 32-35.
37. Yu M, Stott S, Toner M, Maheswaran S, Haber DA (2011) Circulating tumor cells: Approaches to isolation and characterization. J Cell Biol 192(3): 373-382.